Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine in Migraine
NCT07764783Phase 2Not yet recruiting
- Sponsor
- Association of Migraine Disorders
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lidocaine 10% oropharyngeal spray in migraine, Facial pain and Headache (2 arms), sponsored by Association of Migraine Disorders. Primary endpoints: Acute headache pain at 1 month, Acute facial pain or pressure at 1 month and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
migraineFacial painHeadache
Beyond the preview
Go deeper on NCT07764783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07764783.